Chemotherapy Toxicity GOG 273 Study

Chemotherapy Toxicity GOG 273 Study

Share this:

Chemotherapy toxicity in elderly women with ovarian, primary peritoneal or fallopian tube cancer.

PROTOCOL ID

GOG 273

PROTOCOL DESCRIPTION

The incidence of cancer is expected to increase as life expectancy increases. With the anticipation of a large, aging society of baby boomers, it is predicted that the incidence of ovarian cancer in the elderly, and potentially the extremely elderly, will increase. Small numbers of elderly ovarian cancer patients are enrolled on clinical trials with the greatest impediment to enrollment being physicians' perceptions about age and tolerance of chemotherapy toxicity.

The major goal of this study is to see if physicians can predict how women will tolerate and complete chemotherapy as prescribed using simple assessments looking at your ability to do activities of daily living. Another goal of the study is to look at how chemotherapy works in older women with cancer.

ELIGIBILITY CRITERIA

Patients MUST:

  • Patients must have a confirmed diagnosis of adenocarcinoma of the ovary, peritoneum or fallopian tube.
  • Patients must have received NO previous treatment for this cancer other than surgery.
  • Patients must have adequate: Bone Marrow Function, Hepatic Function, and Renal Function.
  • Patients must be age 70 years old or older.
  • Patients must be recovered from the effects of recent surgery.

Primary Investigator(s)

Janet L. Osborne, M.D.

Contact Information

Vickie Yates, RN
Clinical Research Nurse Coordinator
Phone: 540-204-7635
Email: vlyates@carilionclinic.org